ABSTRACT
Benzo-fused dipyrrins are π-extended analogs of conventional dipyrrins, which exhibit bathochromically shifted absorption and possess the synthetic capability to bind various metal ions. We aimed to investigate the synthetic potential of benzo-fused dipyrrins in the complexation with transition metals. Two new complexes with Pd2+ and Pt2+ were synthesized and characterized. X-ray crystallography reveals that both complexes exhibit a zigzag geometry with square planar coordination of the central metal. The Pd2+ complex possesses a very weak fluorescence at 665 nm, while the Pt2+ complex is completely nonemissive. Transient absorption spectroscopy confirmed triplet excited state formation for both complexes; however, they are short-lived and no phosphorescence was observed even at 77K. DFT calculations support the experimental observation, revealing the existence of the low-lying ligand-metal charge-transfer (LMCT) triplet state acting as an energy sink.
ABSTRACT
Arsenoplatins are adducts of two chemically important anticancer drugs, cisplatin and arsenic trioxide, that have a Pt(II) bond to an As(III) hydroxide center. Screens of the NCI-60 human tumor cell lines reveal that arsenoplatin-1 (AP-1), [Pt(µ-NHC(CH3)O)2ClAs(OH)2], the first representative of this novel class of anticancer agents, displays a superior activity profile relative to the parent drugs As2O3 or cisplatin in a majority of cancer cell lines tested. These activity profiles are important because the success of arsenic trioxide in blood cancers (such as APL) has not been seen in solid tumors due to the rapid clearance of arsenous acid from the body. To understand the biological chemistry of these compounds, we evaluated interactions of AP-1 with the two important classes of biomolecules-proteins and DNA. The first structural studies of AP-1 bound to model proteins reveal that platinum(II) binds the Nε of His in a manner that preserves the Pt-As bond. We find that AP-1 readily enters cells and binds to DNA with an intact Pt-As bond (Pt:As ratio of 1). At longer incubation times, however, the Pt:As ratio in DNA samples increases, suggesting that the Pt-As bond breaks and releases the As(OH)2 moiety. We conclude that arsenoplatin-1 has the potential to deliver both Pt and As species to a variety of hematological and solid cancers.
Subject(s)
Antineoplastic Agents/pharmacology , Arsenic Trioxide/analogs & derivatives , Cisplatin/analogs & derivatives , Organoplatinum Compounds/pharmacology , Antineoplastic Agents/chemistry , Arsenic Trioxide/chemistry , Arsenic Trioxide/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Cisplatin/chemistry , Cisplatin/pharmacology , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Molecular Structure , Organoplatinum Compounds/chemistry , Structure-Activity RelationshipABSTRACT
Red emission with sharp bandwidth and high quantum yield is a desired characteristic for organic chromophores in optoelectronic, spintronic, and biomedical applications. Here, we observe circularly polarized luminescence (CPL) with these characteristics from a benzo-fused BODIPY-BINOL complex (1). Using time-resolved optical spectroscopy, electrochemistry, and density functional theory calculations, we showed that the emissive excited state of 1 does not have a charge-transfer (CT) character, unlike that of the regular BODIPY counterpart (2). The rigidity and the lack of CT character make this class of molecules an appealing platform for CPL-active molecules in the red spectral region, with ample room for improvement in the dissymmetry factor and brightness.
ABSTRACT
We demonstrate that because of the efficient generation of triplet excited state under UV or visible-light irradiation, meso-antracenyl-BODIPY donor-acceptor dyad can catalyze atom-transfer radical addition (ATRA) reactions between bromomalonate and alkenes. This finding paves the way for the design and application of the new type of heavy atom-free organic chromophores for photocatalysis.